Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 60

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 60
---
 disease                                                      Global              P-III                
  TAK-660                    Antihemophilic factor [recombinant], PEGylated       Biologic and other      Pediatric Hemophilia A                                                                                         EU                  P-III                
                                                                                                          Hemophilia A                                                                                                   China               P-III                

____________

Note:

(1) Partnership with GSK.

(2) In June 2025, Takeda announced that it filed an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for an additional dosage and administration for patients under the age of 18.

Table of Contents

Plasma-Derived Therapies (PDT)

Takeda has created a dedicated PDT business unit with a focus on managing the business end-to-end, from plasma donation to manufacturing, R& D and commercialization. In PDT, we aspire to develop life-saving plasma-derived therapies, which are essential for patients with a variety of rare and complex chronic diseases. The dedicated R& D organization within PDT is charged with maximizing the value of existing therapies, identifying new targeted therapies, and optimizing efficiencies across the PDT value chain, from plasma donation to product manufacturing. Near-term, our priority is focused on delivering value from our broad immunoglobulin portfolio (HYQVIA, CUVITRU, GAMMAGARD LIQUID and GAMMAGARD S/D) through the pursuit of new indications, geographic expansions and enhanced patient experience through integrated healthcare technologies. Additionally, we are developing next-generation immunoglobulin products with 20% facilitated SCIG (TAK-881) and liquid low IgA IG (TAK-880) and are pursuing other early-stage opportunities (e. g. hypersialylated Immunoglobulin (hsIgG)) that would add to our diversified commercial portfolio of more than 20 therapeutic products distributed worldwide.

Our PDT pipeline in clinical development as of May 8, 2025 (the date of our annual earnings release), along with notes for major subsequent developments thereafter, is as follows:

  Development code                                                   Type of Drug                                                                                  Modality                Indications / additional formulations                                                          Country/      Stage                
  TAK-771 1                                                          Immunoglobulin (IgG) + recombinant hyaluronidase replacement therapy                          Biologic and other      Primary Immunodeficiencies and Secondary Immunodeficiencies                                    Japan         Approved (Dec 2024)  
                                                                                                                                                                                           Chronic inflammatory demyelinating polyradiculoneuropathy and Multifocal Motor